Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new dissolvable dressing stop surgical bleeding faster?

NCT ID NCT07764055

Disease control Sponsor: Medprin Regenerative Medical Technologies Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This trial is testing whether a new absorbable dressing made from oxidized cellulose can safely and effectively stop bleeding during surgery. The study will compare it to a standard hemostatic dressing in about 288 adults undergoing various surgical procedures. The main goal is to see if the new dressing stops bleeding within 5 minutes of application. Participants will be monitored for up to 6 months after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Absorbable multilayer fibrillar regenerated oxidized cellulose dressing
What this could lead to
If successful, this could offer surgeons a new, effective option to control bleeding during operations, potentially improving safety and outcomes.
What could go wrong
This is a non-inferiority trial, so the new dressing may only be as good as, not better than, the existing one. Results are preliminary until the full trial is analyzed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

288 people

The number who actually took part.

Started

Nov 2022

Finished

Mar 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years, any gender. * Patients scheduled for surgical procedures where adjunctive hemostasis is anticipated. * Patient and/or legal guardian has provided written informed consent. Exclusion Criteria: * Participated in another clinical trial within 1 month prior to surgery. * Presence of acute infection. * Severe diseases of vital organs (heart, liver, kidney) or hematological diseases that would make the patient intolerant to surgery. * Known allergy to regenerated oxidized cellulose. * History of severe allergies or severe immunodeficiency. * Severe coagulation dysfunction (e.g., platelet count \< 50×10\^9/L, INR \> 2). * Life expectancy \< 6 months. * Pregnant or breastfeeding women. * Patients deemed non-compliant or unable to complete the study as judged by the investigator. * Unable to understand the study description provided by the investigator. * Any other condition deemed unsuitable for participation by the investigator (e.g., extensive trauma, extremely unstable vital signs, life-threatening massive bleeding).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hemorrhage are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hemorrhage Oxidized regenerated cellulose Surgical bleeding

Contacts and locations

Locations

  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

    Hangzhou, China

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, China

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, China

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, China

  • Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, China

  • Zhejiang Provincial People's Hospital

    Hangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.